stoxline Quote Chart Rank Option Currency Glossary
  
Graphite Bio, Inc. (GRPH)
3.18  -0.09 (-2.75%)    03-21 16:00
Open: 3.2
High: 3.2316
Volume: 299,406
  
Pre. Close: 3.27
Low: 3.05
Market Cap: 185(M)
Technical analysis
2024-05-31 4:53:01 PM
Short term     
Mid term     
Targets 6-month :  3.77 1-year :  4.4
Resists First :  3.23 Second :  3.77
Pivot price 0
Supports First :  3.11 Second :  3.04
MAs MA(5) :  0 MA(20) :  0
MA(100) :  0 MA(250) :  0
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  0 D(3) :  0
RSI RSI(14): 0
52-week High :  3.23 Low :  3.04
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ GRPH ] has closed Bollinger Bands are 0% narrower than normal.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: - -
Low: - -
Close: - -
Company Description

Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Headline News

Thu, 21 Mar 2024
LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress - Business Wire

Tue, 19 Mar 2024
Graphite Bio Approves Merger, Name Change, and Stock Split - TipRanks

Fri, 08 Mar 2024
Graphite Bio Announces Special Dividend Amid Lenz Merger - TipRanks

Fri, 08 Mar 2024
Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics - Business Wire

Tue, 27 Feb 2024
GRAPHITE BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Graphite Bio, Inc. - GRPH - Business Wire

Sat, 27 Jan 2024
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates FNCB, PWFL, DOC, GRPH - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 0 (M)
Held by Insiders 0 (%)
Held by Institutions 0 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) 0 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android